Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lidocaine studies

This article was originally published in The Tan Sheet

Executive Summary

FDA's Anesthetic and Life Support Drugs Advisory Committee will hear a progress report on studies of the metabolism of lidocaine by human liver tissues on the second day of a June 9-10 meeting. FDA has been conducting studies on liver samples to determine if 2,6 xylidine, a lidocaine metabolite, is metabolized by humans; if not, the study would affirm the committee's August 1993 conclusion that studies showing development of nasal tumors in rats exposed to high doses of 2,6 xylidine are not relevant to humans ("The Tan Sheet" Aug. 30, 1993, p. 10). The meeting will convene in Conference Rooms D & E of FDA's Parklawn Building at 8 a.m. on June 10 and 8:30 a.m. on June 9
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel